At Long Last, Spectranetics Turns a Corner
Executive Summary
After 17 straight years of losses, Spectranetics turned its first profit last year. Company officials believe they can sustain profitability going forward.
You may also be interested in...
Spectranetics Delivers on Laser's Promise
After a bright promise in the early 1980s, cardiac lasers fell out of favor due to high complication rates and equivocal clinical results. Laser pioneer Spectranetics faced those problems and more, causing the company to languish in the 1990s. Now its back, with a new marketing partner, US Surgical, in a hot new area, TMR, and a strategy that allows the company to spread its risk.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.